ClinicalTrials.gg
RecruitingNCT05895487Updated Sep 26, 2024

Study on Efficacy, Safety and Durability of the UniLine Prosthesis in the Treatment of Aortic and Mitral Valve Disease

An observational study in Diseases of Mitral and Aortic Valves, Rheumatic Disorders of Mitral and Aortic Valves and Other Congenital Malformations of Aortic and Mitral Valves, sponsored by Closed Joint-Stock Company NeoCor. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Closed Joint-Stock Company NeoCor · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

Acquired heart diseases continue to remain one of the most common causes of cardiac mortality and morbidity. In the Russian Federation, open surgery treatment of acquired valvular heart diseases (AVHD) is performed in more than 40 regions by specialists from 92 healthcare organizations.

Treating aortic or mitral valve disease using the "UniLine" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the "UniLine" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the "UniLine" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of "UniLine" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique.

The aim of the study is to assess the effectiveness, safety, durability of the "UniLine" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis.

In accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions.

Moreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity.

The study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Local Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.

Read the detailed description

Acquired heart diseases continue to remain one of the most common causes of cardiac mortality and morbidity. In Russia, heart valve diseases account for 7 to 25% of all cardiovascular diseases, moreover, they rank third as the cause of heart failure. Prosthetic heart valves commonly used as an effective treatment of acquired valvular heart diseases (AVHD). In the Russian Federation, open surgery treatment of AVHD is performed in more than 40 regions by specialists from 92 healthcare organizations. Surgeries on heart valves, being high-tech care, most effectively prolong the life of patients. Timely treatment of the disease allows 75-95% of patients to return to an active lifestyle and work. The purpose of surgical interventions is to increase life expectancy and to improve the quality of life, which can be achieved via adequate changes in intracardiac hemodynamics and reverse remodeling in the postoperative period.

Bioprosthetic heart valves, unlike most mechanical valves, are characterized by high thromboresistance, optimal (similar to native) hemodynamics parameters and quietness; they improve the quality of life of patients and do not require anticoagulant therapy in the long-term postoperative period. Moreover, bioprosthetic valve dysfunction develops slowly (within a few months or years), meaning that there is time for further examination and preoperative preparation, and a patient's life can be saved.

The "UniLine" bioprosthesis is designed for mitral or aortic valve replacement. This medical device has been used in clinical practice since 2008. Manufacturing of the "UniLine" bioprosthesis involves novel and innovative technologies, including high-precision thickness measurement and laser cutting for the leaflets, which prevents the unfolding of collagen structure along the edge of the cut, and ensures maximum uniformity of the material used, preventing the development of fatigue-induced changes. Unique modeling of leaflets provides complete coaptation. Anticalcification treatment with aminophosphonates contributes to a significant decrease in calcium-binding capacity, which helps to reduce the risk of dysfunction. The absence of synthetic components in the bioprosthesis should reduce the likelihood of endocarditis. Xenopericardium is preserved by using the epoxide compound (diglycidyl ether of ethylene glycol) under low pressure. Each "UniLine" bioprosthesis is subject to mandatory preclinical hydrodynamic assessment in accordance with the National Standards of the Russian Federation (GOST 26997-2003 and GOST 52999-2008). The "UniLine" atrioventricular biological prosthesis is manufactured in standard sizes 26, 28, 30 and 32, the "UniLine" aortic biological prosthesis is manufactured in standard sizes 21, 23, 25.

Treating aortic or mitral valve disease using the "UniLine" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the "UniLine" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the "UniLine" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of "UniLine" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique.

The aim of the study is to assess the effectiveness, safety, durability of the "UniLine" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis.

In accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions.

Moreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity.

The study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll 2000 patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.

02

Conditions studied

  • Diseases of Mitral and Aortic Valves
  • Rheumatic Disorders of Mitral and Aortic Valves
  • Other Congenital Malformations of Aortic and Mitral Valves
  • Valvular Heart Disease (Aortic and Mitral Valves)
  • Mitral Valve Insufficiency and Aortic Valve Insufficiency

Keywords

  • acquired heart diseases
  • mitral valve
  • aortic valve
  • prosthetic heart valves
  • bioprosthetic valves "UniLine"
  • bioprosthetic valve dysfunction
03

In context

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 300 across 228 observational studies indexed under Heart Valve Diseases.

Browse Heart Valve Diseases studies →

Lead sponsor

Closed Joint-Stock Company NeoCor is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 18 years and older who underwent isolated mitral or aortic valve replacement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes aged 18 years and older who underwent isolated mitral or aortic valve replacement using the "UniLine" bioprosthesis
  • No prior heart valve replacement

Exclusion criteria

Exclusion Criteria:

  • The presence of a mechanical or biological prosthesis in another position
  • Prior valve repair
  • Aortic aneurysm repair (ascending aorta)
  • Resection of a left ventricular aneurysm
  • Patients with active cancer and patients with history of cancer
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Long-term safety and durability of the "UniLine" epoxy-treated prosthesis made with xenopericardium in the treatment of isolated mitral and aortic valve diseases

    Long-term safety of the "UniLine" epoxy-treated prosthesis made with xenopericardium in the treatment of isolated mitral and aortic valve diseases will be evaluated by the frequency of complications associated with the valve. Device safety is defined as the absence of severe adverse events associated with the device or procedure, assessed by the following clinical phenomena: 1. Death 2. Severe complications of the heart 3. Life-threatening bleeding 4. Any bioprosthesis-related dysfunction, migration, thrombosis or other complication requiring an open-heart surgery or repeated intervention. 5. Myocardial infarction (or ACS) or progression of a chronic form of ischemia requiring percutaneous coronary intervention or coronary artery bypass grafting 6. Access site complications 7. Stroke

    Time frame: Up to 12 years from the moment of implantation

  2. The long-term durability of the bioprosthesis will be evaluated by assessing the hemodynamic characteristics of the bioprosthetic valve (data obtained by echocardiography).

    1. Peak and mean gradient on the atrioventricular bioprosthesis (as provided by manufacturer manufacturer). 2. The effective orifice area of the bioprosthesis (as provided by manufacturer manufacturer).

    Time frame: Up to 12 years from the moment of implantation

Secondary outcomes

  1. Frequency of adverse events

    Frequency of adverse events

    Time frame: Up to 12 years from the moment of implantation

  2. Frequency of severe adverse events

    Frequency of severe adverse events

    Time frame: Up to 12 years from the moment of implantation

  3. Frequency of adverse events associated with the device

    Frequency of adverse events associated with the device

    Time frame: Up to 12 years from the moment of implantation

  4. Frequency of adverse events associated with the procedure

    Frequency of adverse events associated with the procedure

    Time frame: Up to 12 years from the moment of implantation

  5. The absence of all-cause mortality

    The absence of all-cause mortality

    Time frame: Up to 12 years from the moment of implantation

07

Study locations

1 of 1 sites recruiting
  • Federal State Budgetary Scientific Institution "Research Institute for Complex Issues of Cardiovascilar Diseases"
    Kemerovo, 650002, Russian Federation
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Oct 2025, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
Jun 8, 2023
StartActual
Nov 1, 2022
Primary completionEst.
Oct 1, 2025
CompletionEst.
May 1, 2026
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05895487
Lead sponsor
Closed Joint-Stock Company NeoCor
Collaborators
CT Medical Limited Liability Company, Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Responsible party
Sponsor
First posted
Jun 8, 2023
Start date
Nov 1, 2022
Primary completion
Oct 1, 2025 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Sep 26, 2024

Study contacts

Evgeny Bazdyrev
Contact
clinicresearch@kemcardio.ru
+7 (3842) 644240
Michael Karelin
Contact
karelin@ctmedical.ru
+7 (913) 433 7669
Alexander Bogachev-Prokofiev, MD, PhD
principal investigator · National Medical Research Center named after Academician E.N. Meshalkin
Alexey Evtushenko, MD, PhD
principal investigator · Research Institute for Complex Issues of Cardiovascular Diseases

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion